We provide design support for CRISPR-based disease cell model generation, mechanistic studies, assay development, biomarker development, and HTS drug screening in organoids and organ-on-chip systems—augmented by AI-driven analytics to streamline design, improve predictivity, and accelerate discovery.

We provide expertise in developing assays and methods for therapeutic target classes including GPCRs, ion channels, membrane receptors, kinases, phosphatases, ubiquitin ligases, transcription/translation factors, RNA molecules, and others to accelerate drug discovery. Our focus spans therapeutic areas including oncology, kidney disease, fibrosis, cell therapy, and regenerative medicine.

We provide novel cell line generation strategies tailored to the heterologous production of proteins of interest. Our approach combines targeted knock-in and knockout strategies, vector engineering, HTS expression clone screening, and AI/ML analytics to optimize protein production, purification, and crystallization.

We leverage large-scale EHR datasets (e.g., All of Us, 440K+ participants), genomic, and multi-omics data to uncover population-specific risk factors for complex and rare diseases. We apply AI/ML models for disease modeling, ancestry-aware patient stratification, and risk prediction—informing precision medicine initiatives with tailored insights.